These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33914057)

  • 1. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Tesileanu CMS; van den Bent MJ; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Sabedot TS; Hoogstrate Y; von Deimling A; de Heer I; van IJcken WFJ; Brouwer RWW; Aldape K; Jenkins RB; Dubbink HJ; Kros JM; Wesseling P; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; Noushmehr H; French PJ
    Neuro Oncol; 2021 Sep; 23(9):1547-1559. PubMed ID: 33914057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
    van den Bent MJ; Tesileanu CMS; Wick W; Sanson M; Brandes AA; Clement PM; Erridge S; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; Herrlinger U; Hau P; Dhermain F; de Heer I; Aldape K; Jenkins RB; Dubbink HJ; Kros JM; Wesseling P; Nuyens S; Golfinopoulos V; Gorlia T; French P; Baumert BG
    Lancet Oncol; 2021 Jun; 22(6):813-823. PubMed ID: 34000245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic glioma: current treatment and management.
    Le Rhun E; Taillibert S; Chamberlain MC
    Expert Rev Neurother; 2015 Jun; 15(6):601-20. PubMed ID: 25936680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
    Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
    Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial.
    Draaisma K; Tesileanu CMS; de Heer I; Klein M; Smits M; Reijneveld JC; Clement PM; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Weller M; Chinot OL; Kros JM; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A; Robe PA; van den Bent MJ; French PJ
    Clin Cancer Res; 2022 Jun; 28(11):2440-2448. PubMed ID: 35294545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic astrocytoma.
    Grimm SA; Chamberlain MC
    CNS Oncol; 2016 Jul; 5(3):145-57. PubMed ID: 27230974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
    Tesileanu CMS; Vallentgoed WR; Sanson M; Taal W; Clement PM; Wick W; Brandes AA; Baurain JF; Chinot OL; Wheeler H; Gill S; Griffin M; Rogers L; Rudà R; Weller M; McBain C; Reijneveld J; Enting RH; Caparrotti F; Lesimple T; Clenton S; Gijtenbeek A; Lim E; de Vos F; Mulholland PJ; Taphoorn MJB; de Heer I; Hoogstrate Y; de Wit M; Boggiani L; Venneker S; Oosting J; Bovée JVMG; Erridge S; Vogelbaum MA; Nowak AK; Mason WP; Kros JM; Wesseling P; Aldape K; Jenkins RB; Dubbink HJ; Baumert B; Golfinopoulos V; Gorlia T; van den Bent M; French PJ
    Acta Neuropathol; 2021 Jun; 141(6):945-957. PubMed ID: 33740099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
    Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
    Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
    Tesileanu CMS; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Aldape K; Jenkins RB; Kros JM; Wesseling P; von Deimling A; Hoogstrate Y; de Heer I; Atmodimedjo PN; Dubbink HJ; Brouwer RWW; van IJcken WFJ; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; French PJ; van den Bent MJ
    Clin Cancer Res; 2022 Jun; 28(12):2527-2535. PubMed ID: 35275197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
    Abrunhosa-Branquinho AN; Bar-Deroma R; Collette S; Clementel E; Liu Y; Hurkmans CW; Feuvret L; Van Beek K; van den Bent M; Baumert BG; Weber DC
    Radiother Oncol; 2018 May; 127(2):292-298. PubMed ID: 29606522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anaplastic glioma.
    Wick W; Wiestler B; Platten M
    Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
    Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.